The proliferation hypothesis suggests that ATRA-ATO therapy targets the PML-RARα fusion protein to induce differentiation and maturation of APL cells; however, the differentiated granulocytes retain proliferative capacity, and an increased number of divisions during differentiation results in a rapid surge in mature granulocyte counts within a short period. The gene discussed is RARA; the disease is acute promyelocytic leukemia.